keyword
MENU ▼
Read by QxMD icon Read
search

Crohn' disease

keyword
https://www.readbyqxmd.com/read/28545190/radiation-exposure-in-patients-with-inflammatory-bowel-disease-a-fourteen-year-review-at-a-tertiary-care-centre-in-malaysia
#1
Jeevinesh Naidu, Zhiqin Wong, Shanthi Palaniappan, Chai Soon Ngiu, Raja Affendi Raja Ali
Background and Aims: Patients with inflammatory bowel disease (IBD) are subjected to a large amount of ionizing radiation during the course of their illness. This may increase their risk of malignancy to a greater level than that due to the disease itself. In Caucasian patients with Crohn’s disease, this has been well documented and recommendations are in place to avoid high radiation imaging protocols. However, there are limited data available on radiation exposure in Asian IBD patients.We therefore sought to identify total radiation exposure and any differences between ethnically diverse ulcerative colitis (UC) and Crohn’s disease (CD) patients at our centre along with determining factors that may contribute to any variation...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28542425/association-of-atg16l1-gene-haplotype-with-inflammatory-bowel-disease-in-indians
#2
Srinivasan Pugazhendhi, Kirankumar Baskaran, Srikanth Santhanam, Balakrishnan S Ramakrishna
Inflammatory bowel disease (IBD) is characterized by multigenic inheritance. Defects in autophagy related genes are considered to show genetic heterogeneity between populations. We evaluated the association of several single nucleotide polymorphisms (SNPs) in the autophagy related 16 like 1 (ATG16L1) gene with IBD in Indians. The ATG16L1 gene was genotyped for ten different SNPs using DNA extracted from peripheral blood of 234 patients with Crohn's disease (CD), 249 patients with ulcerative colitis (UC) and 393 healthy controls The SNPs rs2241880, rs4663396, rs3792106, rs10210302, rs3792109, rs2241877, rs6737398, rs11682898, rs4663402 and rs4663421 were genotyped using the Sequenom MassArray platform...
2017: PloS One
https://www.readbyqxmd.com/read/28542350/t0001-a-variant-of-tnfr2-fc-fusion-protein-exhibits-improved-fc-effector-functions-through-increased-binding-to-membrane-bound-tnf%C3%AE
#3
Yijun Shen, Gang Li, Chunying Gu, Ben Chen, Aihua Chen, Hua Li, Bei Gao, Chencai Liang, Jingsong Wu, Tong Yang, Li Jin, Yong Su
T0001 is a recombinant human TNFR-Fc fusion protein mutant; it exhibits higher affinity to TNFα than etanercept and is now being tested in a Phase 1 study in China (ClinicalTrials.gov Identifier: NCT02481180). T0001 can inhibit the binding of soluble TNFα (sTNFα) or membrane-bound TNFα (mTNFα) to TNF receptors. When bound to mTNFα, the Fc-bearing TNFα antagonists have the potential to induce Fc-mediated effects, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CDC) as well as outside-to-inside signals (apoptosis mainly)...
2017: PloS One
https://www.readbyqxmd.com/read/28542298/early-anti-tnf-immunomodulator-therapy-is-associated-with-better-long-term-clinical-outcomes-in-asian-patients-with-crohn-s-disease-with-poor-prognostic-factors
#4
Eun Hye Oh, Kyunghwan Oh, Minkyu Han, Hyungil Seo, Kiju Chang, Sun-Ho Lee, Gwang-Un Kim, Eun Mi Song, Myeongsook Seo, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Although early treatment of Crohn's disease (CD) patients with anti-tumor necrosis factor (TNF) agents or immunomodulators (IMs) may improve long-term outcomes, especially those with poor prognostic factors, their effectiveness in Asians remains unclear. In this study, Korean patients with CD naïve to both intestinal surgery and intestinal complications, and with at least two risk factors for progression (diagnosis at age <40 years, systemic corticosteroid treatment <3 months after diagnosis, and perianal fistula at diagnosis) were retrospectively analyzed...
2017: PloS One
https://www.readbyqxmd.com/read/28542115/exposure-to-oral-contraceptives-increases-the-risk-for-development-of-inflammatory-bowel-disease-a-meta-analysis-of-case-controlled-and-cohort-studies
#5
Ronald Ortizo, Stephanie Y Lee, Emily T Nguyen, Mohammad Mazen Jamal, Matthew M Bechtold, Douglas L Nguyen
BACKGROUND: The oral contraceptive pill (OCP) is a widely used method of contraception. There have been conflicting studies linking the use of OCPs to the development of inflammatory bowel disease (IBD). The intent of this meta-analysis is to better define the association between OCP exposure and the risk for development of IBD. METHODS: A thorough search of multiple databases, including Scopus, Cochrane, MEDLINE/PubMed, and CINAHL, and abstracts from major gastroenterology meetings was performed (October, 2016)...
May 24, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28542043/induction-therapy-with-biosimilar-infliximab-in-children-with-crohn-s-disease
#6
Joanna Sieczkowska-Golub, Monika Meglicka, Anna Plocek, Aleksandra Banaszkiewicz, Dorota Jarzębicka, Ewa Toporowska-Kowalska, Agnieszka Gawronska, Grzegorz Oracz, Jaroslaw Kierkus
INTRODUCTION: In most European countries, an infliximab biosimilar (CT-P13) is currently in common use. In vitro and in vivo studies have proved a high similarity between CT-P13 and the reference infliximab. CT-P13 was licensed for use in patients with Crohn's diseases (CD) based on the extrapolation of data from preclinical studies and clinical trials in rheumatology indications. The aim of this study was to assess the similarity between CT-P13 and the originator infliximab in induction therapy in CD paediatric patients...
May 24, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28541872/chronic-paracoccidioidmycosis-in-a-woman-with-crohn-disease
#7
Harim Tavares Dos Santos, Bruno Augusto Benevenuto de Andrade, Darcy Fernandes, Daphine Caxias Travassos, Andreia Bufalino
We report a rare case of chronic paracoccidioidomycosis(PCM) in a woman with Crohn disease in the setting of treatment with azathioprine and mesalazine. Serum tests for antigens to Paracoccidioides brasiliensis, Histoplasma capsulatum, and Aspergillus fumigatus were negative. An incisional biopsy of an oral lesion with periodic acid-schiff and Grocott-methenamine silver stains revealed chronic granulomatous inflammation with multinucleated giant cells with Paracoccidioides brasiliensis within the cytoplasm, confirming the diagnosis of PCM...
April 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28540051/faecal-microbiota-transplantation-where-did-it-start-what-have-studies-taught-us-where-is-it-going
#8
REVIEW
Ryan M Chanyi, Laura Craven, Brandon Harvey, Gregor Reid, Michael J Silverman, Jeremy P Burton
The composition and activity of microorganisms in the gut, the microbiome, is emerging as an important factor to consider with regard to the treatment of many diseases. Dysbiosis of the normal community has been implicated in inflammatory bowel disease, Crohn's disease, diabetes and, most notoriously, Clostridium difficile infection. In Canada, the leading treatment strategy for recalcitrant C. difficile infection is to receive faecal material which by nature is filled with microorganisms and their metabolites, from a healthy individual, known as a faecal microbiota transplantation...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28539742/neutralization-of-inflammation-by-inhibiting-in-vitro-and-in-vivo-secretory-phospholipase-a2-by-ethanol-extract-of-boerhaavia-diffusa-l
#9
Aladahalli S Giresha, Siddanakoppalu N Pramod, A D Sathisha, K K Dharmappa
BACKGROUND: Inflammation is a normal and necessary prerequisite to healing of the injured tissues. Inflammation contributes to all disease process including immunity, vascular pathology, trauma, sepsis, chemical, and metabolic injuries. The secretory phospholipase A2 (sPLA2) is a key enzyme in the production of pro-inflammatory mediators in chronic inflammatory disorders such as rheumatoid arthritis, coronary heart disease, diabetes, and asthma. The sPLA2 also contribute to neuroinflammatory disorders such as Parkinson's, Alzheimer's, and Crohn's disease...
April 2017: Pharmacognosy Research
https://www.readbyqxmd.com/read/28538894/sweet-s-syndrome-associated-with-crohn-s-disease
#10
Caren Dos Santos Lima, Roberta Duarte Bezerra Pinto, Heliana Freitas de Oliveira Góes, Simone de Abreu Neves Salles, Enoi Aparecida Guedes Vilar, Carla Dos Santos Lima
Sweet's syndrome is an uncommon benign skin disorder, whose pathogenesis remains unknown. Its classic form is more common in women and presents itself as papular-nodular, painful and erythematous or violaceous lesions. It mainly affects the face, neck, and upper limbs. Fever and neutrophilic leukocytosis are also common features. Although it is considered a systemic disease marker in more than half of patients, the association of this condition with Crohn's disease is rare, with few cases reported in the literature, of which, none in Brazil...
March 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28538364/thalidomide-results-in-diminished-ovarian-reserve-in-reproductive-age-female-ibd-patients
#11
Xiang Peng, Min Zhi, Ming Wei, Ting-Ting Li, Min Zhang, Yuan-Qi Zhang, Huan He, Mingli Su, Wei Wang, Jun-Rong Chen, Jian Tang, Xiang Gao, Pin-Jin Hu, Xiao-Yan Liang
The effectiveness of thalidomide in treating inflammatory bowel disease (IBD) has been widely recognized. Meanwhile, many serious adverse drug reactions have been observed, but no know reports on ovarian reserve function.Female patients, ranging in age between 18 and 40, were referred to our institution to undergo sex hormone detection and ultrasonic scanning for ovarian function assessment, between February 1, 2016 and September 31, 2016.Thirty-three patients treated with thalidomide (group A), 73 patients without thalidomide (group B), and 78 healthy women as control were studied...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28537467/dose-escalation-of-biologics-in-crohn-s-disease-critical-review-of-observational-studies
#12
Thomas R Einarson, Basil G Bereza, Xin Ying Lee, Filippo Lelli
BACKGROUND: Biologics used to treat Crohn's disease (CD) may lose their effect over time, requiring dose escalation. Little information is available on this topic. AIM: To summarize rates of dose escalation, duration, de-escalation in observational studies of CD in adults treated with adalimumab, infliximab, and vedolizumab in Europe. METHODS: Two independent investigators searched Medline and Embase for observational studies published 1998-2015 and proceedings from 4 major scientific meetings...
May 24, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28535243/effect-of-crohn-disease-biologics
#13
(no author information available yet)
No abstract text is available yet for this article.
May 23, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28534335/-consistency-analysis-between-preoperative-ct-enterography-and-intraoperative-findings-in-patients-undergoing-surgery-for-crohn-s-disease
#14
Jianbo Yang, Jianfeng Gong, Yi Li, Lili Gu, Weiming Zhu, Jieshou Li
OBJECTIVE: To evaluate the diagnostic value of preoperative CT enterography (CTE) on obstruction, fistula and abscess formation compared to intraoperative findings in patients undergoing surgery for Crohn's disease(CD), aiming to provide reference to clinical practice. METHODS: Preoperative CTE data of 176 CD patients confirmed by clinic, endoscopy, imaging, operation and pathology at the Department of General Surgery in Nanjing Jinling Hospital from January 2013 to December 2015 were enrolled in retrospective cohort study...
May 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28534264/adherence-to-an-elemental-diet-for-preventing-postoperative-recurrence-of-crohn-s-disease
#15
Nobuyoshi Ohara, Tsunekazu Mizushima, Hideki Iijima, Hidekazu Takahashi, Satoshi Hiyama, Naotsugu Haraguchi, Takahiro Inoue, Junichi Nishimura, Shinichiro Shinzaki, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
PURPOSE: An elemental diet (ED) can suppress inflammation in patients with Crohn's disease (CD); however, adherence to this diet is difficult. We examined the correlation between ED adherence and the postoperative recurrence of CD. METHODS: The subjects of this study were 38 patients who underwent intestinal resection with anastomosis. We defined ED adherence as consuming the average daily ED dose (≥900 kcal/day) for 2 years after surgery. Patients who did not adhere to the ED were allocated to the non-ED group...
May 22, 2017: Surgery Today
https://www.readbyqxmd.com/read/28534191/tgf-%C3%AE-in-inflammatory-bowel-disease-a-key-regulator-of-immune-cells-epithelium-and-the-intestinal-microbiota
#16
REVIEW
Sozaburo Ihara, Yoshihiro Hirata, Kazuhiko Koike
Inflammatory bowel disease (IBD) is defined as chronic intestinal inflammation, and includes ulcerative colitis and Crohn's disease. Multiple factors are involved in the pathogenesis of IBD, and the condition is characterized by aberrant mucosal immune reactions to intestinal microbes in genetically susceptible hosts. Transforming growth factor-β (TGF-β) is an immune-suppressive cytokine produced by many cell types and activated by integrins. Active TGF-β binds to its receptor and regulates mucosal immune reactions through the TGF-β signaling pathway...
May 22, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28533995/crohn-s-disease-and-ulcerative-colitis-show-unique-cytokine-profiles
#17
Zoltan H Nemeth, Dorian A Bogdanovski, Patricia Barratt-Stopper, Samantha R Paglinco, Luca Antonioli, Rolando H Rolandelli
INTRODUCTION: Networks of cytokines have been implicated in both forms of inflammatory bowel disease (IBD): Crohn's disease (CD) and ulcerative colitis (UC). While CD has associated with T-helper type 1 (Th1) immune responses, UC shows Th2 patterns. Recent studies reported that the inflamed intestinal regions in both CD and UC are significantly infiltrated with a newly described set of T helper, the Th17 cells. These cells have unique cytokine responses. These findings prompted us to further explore the cytokine profiles of CD and UC with a special focus on the Th2 and Th17 related mediators...
April 19, 2017: Curēus
https://www.readbyqxmd.com/read/28533923/clinical-and-economic-impact-of-infliximab-one-hour-infusion-protocol-in-patients-with-inflammatory-bowel-diseases-a-multicenter-study
#18
Anna Viola, Giuseppe Costantino, Antonino Carlo Privitera, Fabrizio Bossa, Angelo Lauria, Laurino Grossi, Maria Beatrice Principi, Nicola Della Valle, Maria Cappello
AIM: To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS: All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity...
May 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28533920/inflammatory-bowel-disease-efficient-remission-maintenance-is-crucial-for-cost-containment
#19
REVIEW
Giovanni C Actis, Rinaldo Pellicano
The inflammatory bowel diseases (IBD) are chronic incurable inflammatory disorders of the gut. Some 10% run a downhill course, requiring emergency medical support and often surgery; another small subset are monogenic, and, threatening pediatric patients, are the challenge of these days. The majority of the IBDs, however, are polygenic low-penetrance diseases, running a lifetime waxing-and-waning course. The prevalent trend is towards a slow worsening and steady cost increase. Each and all drugs of the available arsenal exhibit strengths and weaknesses: Mesalamines are chiefly effectively for mild-moderate colitis, and do not work in Crohn's; steroids do not control some 40% of the ulcerative colitis cases, and are not indicated for Crohn's; thiopurines are effective in the maintenance of the IBDs but do not prevent relapses on withdrawal; biologics are still being used empirically (not monitored) causing further increase of their cost over that of hospitalization...
May 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28533919/combination-therapy-for-inflammatory-bowel-disease
#20
REVIEW
Keith S Sultan, Joshua C Berkowitz, Sundas Khan
Biologic therapies such as infliximab and adalimumab have become mainstays of treatment for inflammatory bowel disease. Early studies suggested that combination therapy (CT) with infliximab and an immunomodulator drug such as azathioprine may help optimize biologic pharmacokinetics, minimize immunogenicity, and improve outcomes. The landmark SONIC trial in Crohn's disease and the UC SUCCESS trial in ulcerative colitis demonstrated CT with infliximab and azathioprine to be superior to monotherapy with either agent alone at inducing clinical remission in treatment naïve patients with moderate to severe disease...
May 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
keyword
keyword
4025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"